Douglas Dreffer, MD
Family Medicine · Derry, NHNPI 1316940802
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,818, 2.5 times the $731 reported in 2019. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$625
- Lilly USA, LLC$575
- AstraZeneca$562
- Novo Nordisk$350
- Boehringer Ingelheim$336
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,089100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $1,074 |
| Pfizer | 46 | $625 |
| Lilly USA, LLC | 33 | $575 |
| AstraZeneca | 30 | $562 |
| Novo Nordisk | 18 | $350 |
| Boehringer Ingelheim | 17 | $336 |
| GSK | 15 | $263 |
| Merck | 9 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $175 |
| Collegium Pharmaceutical, Inc. | 6 | $118 |
| Neurocrine Biosciences, Inc. | 4 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $87 |
| Exact Sciences | 5 | $80 |
| Johnson & Johnson | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $76 |
| Abiomed | 2 | $67 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Amgen | 2 | $37 |
| Astellas Pharma US Inc | 2 | $31 |
| Bayer | 1 | $31 |
| Medtronic | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| Viiv Healthcare Company | 1 | $19 |
| Si-bone, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $15 |
| Circassia Inc. | 1 | $13 |
How this compares
$5,089 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $94,348 |
| JardianceEmpagliflozin | 15 | $25,610 |
| MounjaroTirzepatide | 27 | $25,454 |
| OzempicSemaglutide | 16 | $14,547 |
| NexiumEsomeprazole Magnesium | 18 | $11,103 |
| XareltoRivaroxaban | 11 | $8,768 |
| FarxigaDapagliflozin Propanediol | 11 | $8,595 |
| Atorvastatin Calcium | 339 | $2,913 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $2,565 |
| Oxycodone Hcl | 125 | $1,995 |
| Gabapentin | 93 | $1,948 |
| Lisinopril | 210 | $1,659 |
| Levothyroxine Sodium | 157 | $1,544 |
| ValacyclovirValacyclovir Hcl | 26 | $1,471 |
| Omeprazole | 113 | $1,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $625 | $94,34889 claims |
| Boehringer IngelheimJardiance | $336 | $25,61015 claims |
| Lilly USA, LLCMounjaro | $575 | $25,45427 claims |
| AstraZenecaNexium, Farxiga | $562 | $19,69829 claims |
| Novo NordiskOzempic | $350 | $14,54716 claims |
| Johnson & JohnsonXarelto | $78 | $8,76811 claims |
| AbbVieSynthroid | $1,074 | $1,06527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Derry
- Robyn StewartDerry$8K
- John WheelerDerry$5K
- John DaleyDerry$5K
- Michael MaroldaDerry$5K
- Katelyn IsherwoodDerry$3K
- Sarah MuraiDerry$2K
- Cristi EgenolfDerry$2K
- Kristin BroughtonDerry$1K
- Scott LowDerry$1K
- Mark BallentynePortsmouth$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.